Pharmicell Co., Ltd.
Quick facts
Phase 3 pipeline
- Cellgram-LC · Immunology / Regenerative Medicine
Cellgram-LC is an allogeneic mesenchymal stem cell therapy that modulates immune responses and promotes tissue repair through paracrine signaling. - Hearticellgram-AMI · Cardiovascular
Hearticellgram-AMI is an autologous bone marrow-derived cell therapy that promotes cardiac regeneration and repair following acute myocardial infarction.
Phase 2 pipeline
- Cellgram-ED · Oncology
Cellgram-ED is a small molecule that targets the CD47/SIRPα axis to modulate the immune response. - Livercellgram · Gastroenterology
Phase 1 pipeline
- Cellgram-CKD
Cellgram-CKD is a cell-based therapy designed to promote kidney tissue regeneration and improve renal function in chronic kidney disease patients.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Pharmicell Co., Ltd.
What is Pharmicell Co., Ltd.'s pipeline?
Pharmicell Co., Ltd. has 2 drugs in Phase 3, 2 in Phase 2, 1 in Phase 1. Late-stage candidates include Cellgram-LC, Hearticellgram-AMI.
Related
- Sector hub: All tracked pharma companies